Nachrichten zur Hims & Hers Health Aktie

HIMS builds a digital-first healthcare platform, integrating telehealth, AI and personalized treatments while expanding globally and into new specialties.…

HIMS builds a digital-first healthcare platform, integrating telehealth, AI and personalized treatments while expanding globally and into new specialties.…

Novo Nordisk (NVO) stock is in focus as the company launches a Wegovy subscription program via telehealth firms including Hims…

HIMS builds a digital-first healthcare platform, integrating telehealth, AI and personalized treatments while expanding globally and into new specialties.…

Hims & Hers Health (NYSE:HIMS) has launched access to Novo Nordisk FDA-approved GLP-1 medications for eligible patients.The offering includes a…

In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $18.78, denoting a -3.1%…

In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $18.78, denoting a -3.1%…

Price-action only: Hims & Hers Health Inc. Class A (HIMS) movements set the tone for institutional models. Why (HIMS) Price…

New York (www.aktiencheck.de) - Hims & Hers Health-Aktienanalyse von TD Cowen:Die Analysten von TD Cowen stufen die Aktie von Hims…

Recent performance snapshotHims & Hers Health (HIMS) has drawn investor attention after a mixed run, with the share price near…

Hims & Hers Health trades at $19.38 today, down 7.09%. Check out the latest price action and daily performance update.…

SG Americas Securities LLC raised its holdings in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 25.6%…

Hims & Hers Health Inc. stocks have been trading down by -7.02% amid cautious investor sentiment over leadership changes. Key…

TD Cowen lowered their target price on shares of Hims & Hers Health from $25.00 to $23.00 and set a…

Hims & Hers Health announced that, as of yesterday, it is providing direct access to Wegovy tablets, Wegovy injections,…

Hims & Hers Health ( ($HIMS) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual…

Hims & Hers Health shares rallied to ~$27 after the early-March Novo deal before resetting to ~$20. Click here to…

TD Cowen lowered the firm’s price target on Hims Hers to $23 from $25 and keeps a Hold rating…

Hims & Hers began by dismantling the barriers to essential care, turning stigmatized conversations into accessible, evidence-based solutions for hair…

Charlotte (www.aktiencheck.de) - Hims & Hers Health-Aktienanalyse von BofA Securities:Allen Lutz, Analyst von BofA Securities, stuft die Aktie von Hims…

Hims & Hers Health, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Maria Ripps from…

Canaccord reiterates Hims and Hers stock rating on Novo launch…

Hims & Hers is moving toward branded GLP-1s and deeper pharma partnerships, shifting to a potential platform for drug distribution.…

The average one-year price target for Hims & Hers Health (NYSE:HIMS) has been revised to $25.63 / share. This is…

Low-cost healthcare services provider Hims Hers ($HIMS) on Thursday disclosed the availability of approved versions of Novo Nordisk’s ($NVO)…

Hims and Hers stock price target maintained at $23 by BofA Securities…

Hims and Hers stock price target maintained at $23 by BofA Securities…

Hims and Hers stock price target maintained at $23 by BofA Securities…

US telehealth giant Hims & Hers’ USD 1.15bn acquisition in February of Australian digital health company Eucalyptus is expected to significantly shake…

Key Takeaways: Hims & Hers Health (HIMS) expands its product offerings by selling Novo Nordisks GLP-1 drugs,…